Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report

Optimal management of EGFR-mutated NSCLC with leptomeningeal (LM) disease progression through EGFR tyrosine kinase inhibitor remains unclear. We present a 39-year-old man with EGFR-mutated NSCLC and LM disease progression through osimertinib 80 mg daily, with subsequent durable radiographic and symp...

Descripción completa

Detalles Bibliográficos
Autores principales: Merkhofer, Cristina M., Baik, Christina S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474424/
https://www.ncbi.nlm.nih.gov/pubmed/34590025
http://dx.doi.org/10.1016/j.jtocrr.2021.100177
_version_ 1784575218045419520
author Merkhofer, Cristina M.
Baik, Christina S.
author_facet Merkhofer, Cristina M.
Baik, Christina S.
author_sort Merkhofer, Cristina M.
collection PubMed
description Optimal management of EGFR-mutated NSCLC with leptomeningeal (LM) disease progression through EGFR tyrosine kinase inhibitor remains unclear. We present a 39-year-old man with EGFR-mutated NSCLC and LM disease progression through osimertinib 80 mg daily, with subsequent durable radiographic and symptomatic response to systemic pemetrexed in combination with osimertinib. This builds on the limited data evaluating LM disease response to systemic pemetrexed and lends further support to consideration of this treatment strategy.
format Online
Article
Text
id pubmed-8474424
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84744242021-09-28 Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report Merkhofer, Cristina M. Baik, Christina S. JTO Clin Res Rep Case Report Optimal management of EGFR-mutated NSCLC with leptomeningeal (LM) disease progression through EGFR tyrosine kinase inhibitor remains unclear. We present a 39-year-old man with EGFR-mutated NSCLC and LM disease progression through osimertinib 80 mg daily, with subsequent durable radiographic and symptomatic response to systemic pemetrexed in combination with osimertinib. This builds on the limited data evaluating LM disease response to systemic pemetrexed and lends further support to consideration of this treatment strategy. Elsevier 2021-04-25 /pmc/articles/PMC8474424/ /pubmed/34590025 http://dx.doi.org/10.1016/j.jtocrr.2021.100177 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Merkhofer, Cristina M.
Baik, Christina S.
Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report
title Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report
title_full Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report
title_fullStr Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report
title_full_unstemmed Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report
title_short Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report
title_sort durable response of leptomeningeal disease with osimertinib and pemetrexed in egfr-mutated metastatic nsclc: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474424/
https://www.ncbi.nlm.nih.gov/pubmed/34590025
http://dx.doi.org/10.1016/j.jtocrr.2021.100177
work_keys_str_mv AT merkhofercristinam durableresponseofleptomeningealdiseasewithosimertinibandpemetrexedinegfrmutatedmetastaticnsclcacasereport
AT baikchristinas durableresponseofleptomeningealdiseasewithosimertinibandpemetrexedinegfrmutatedmetastaticnsclcacasereport

Ejemplares similares